Second allogeneic stem cell transplantation for XMEN disease

Area of Science:

• Immunology
• Genetics
• Hematology

Background:

• X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia (XMEN) disease results from MAGT1 gene mutations.
• Adult patients often face delayed diagnosis, increasing treatment complexity.
• Allogeneic stem-cell transplantation is curative but carries high mortality, particularly in adults.

Purpose of the Study:

• To report the first successful second allogeneic stem-cell transplant in an adult with XMEN disease.
• To highlight the potential of stem cell transplantation as a curative option for adult XMEN patients.

Main Methods:

• Case report of a patient with XMEN disease undergoing a second allogeneic stem-cell transplant.
• Management of post-transplant complications, including impaired platelet aggregation and mucosal hemorrhage.
• Monitoring platelet levels to prevent life-threatening bleeding.

Main Results:

• Successful engraftment following the second allogeneic stem-cell transplant.
• Demonstrated the feasibility of a second transplant in managing XMEN disease.
• Controlled life-threatening mucosal hemorrhage through meticulous platelet support.

Conclusions:

• Second allogeneic stem-cell transplantation is a viable curative strategy for adult XMEN disease patients with suitable donors.
• Aggressive platelet management is crucial to mitigate fatal hemorrhage risks during post-transplant aplasia.
• Early diagnosis and genetic confirmation are vital for timely intervention in XMEN disease.